Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

NCT02641457 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Glaucoma
Rubeosis Iridis

Interventions

DRUG: Aflibercept
DRUG: Ranibizumab

Sponsor

Instituto de Olhos de Goiania